Late-stage clinical biopharmaceutical company Definium Therapeutics Inc (Nasdaq:DFTX) on Wednesday reported positive topline results from its Phase 3 Voyage study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 micrograms in adults with generalised anxiety disorder (GAD).
The study met its primary and all key secondary efficacy endpoints, with DT120 ODT producing a placebo-adjusted improvement of 5.4 points in the Hamilton Anxiety Rating Scale score at Week 12 (p
SoftOx doses first patient in SIS-03 proof-of-concept trial
BSF secures exclusive global commercialisation partnership for ETSYL
Aureka Biotechnologies raises USD100m to build biological world model for drug discovery
AbCellera reports positive Phase 2 results for menopause treatment ABCL635
Bristol Myers Squibb to invest USD2.3bn in Houston manufacturing campus
BeOne Medicines and Revolution Medicines expand oncology collaboration
Almirall partners with CrystalO to develop small molecules for medical dermatology
Sobi partners with Innate Pharma to advance lacutamab in T-cell lymphoma
Saniona grants AstronauTx worldwide rights to neurological disease programme
Oculis signs agreement to acquire Privosegtor from Accure Therapeutics
Biophytis receives Brazilian approval for Phase 2 obesity trial of BIO101
ImmuPharma selects Kymos Group as bioanalytical partner for Kapiglucagon
Neurocrine Biosciences initiates Phase 1 study of GLP-1/GIP/glucagon receptor triple agonist
Akeso Advances reports first patient dosed in AK146D1 combined with ivonescimab breast cancer study